Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 126 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus, Type 2
Interventions
IcoSema, Insulin icodec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
110
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 90 more
Conditions
Weight Management
Interventions
Elecoglipron, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 53 more
Conditions
Overweight, Obesity
Interventions
Gelesis100, placebo
Device
Lead sponsor
Gelesis, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
25
States / cities
Anaheim, California • San Diego, California • Tustin, California + 21 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function

NCT00845182
Conditions
Type 2 Diabetes, Healthy, Impaired Glucose Tolerance
Interventions
Pioglitazone, Exenatide, Pioglitazone and Exenatide
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Conditions
Obesity, Overweight, Type 2 Diabetes
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Sun City West, Arizona • Tucson, Arizona • San Ramon, California + 31 more
Conditions
Type 2 Diabetes, Overweight, ASCVD
Interventions
Dulaglutide, Semaglutide, Tirzepatide, Sitagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60,000 participants
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Heart Failure, Type 2 Diabetes
Interventions
aerobic exercise training
Behavioral
Lead sponsor
Duke University
Other
Eligibility
50 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Type 1 Diabetes Mellitus
Interventions
Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Terminated Phase 2 Interventional Results available

A Study of LY2599506 in Patients With Type 2 Diabetes

NCT01024244
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, LY2599506
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Topeka, Kansas • Toms River, New Jersey • Syracuse, New York
Conditions
Diabetes Melliuts, Type 2
Interventions
Placebo, 25 mg PF-05231023, 50 mg PF-05231023, 100 mg PF-05231023, 150 mg PF-05231023
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Anaheim, California • Chula Vista, California • Walnut Creek, California + 10 more
Conditions
Obesity, Overweight
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
45
States / cities
Huntington Park, California • Los Angeles, California • Montclair, California + 42 more
Conditions
Obesity, Overweight
Interventions
Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
41
States / cities
Tuscaloosa, Alabama • Scottsdale, Arizona • Escondido, California + 37 more
Conditions
Overweight, Obesity
Interventions
Macupatide, Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 37 more
Conditions
Obesity, Type 2 Diabetes
Interventions
High fiber vs. low-carbohydrate diets
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Loma Linda, California
Conditions
PCOS (Polycystic Ovary Syndrome), Obese Adolescents, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight Adolescents, Irregular Menstrual Cycle, Irregular Menstrual Cycles, Hirsutism, Hyperandrogenism
Interventions
Beef+
Other
Lead sponsor
Texas A&M University
Other
Eligibility
11 Years to 17 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
College Station, Texas
Conditions
Diabetes Mellitus, Type 2
Interventions
Retatrutide, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
38
States / cities
Birmingham, Alabama • Escondido, California • Long Beach, California + 34 more
Conditions
Diabetes Mellitus
Interventions
Effects of Pulsatile IV insulin on Diabetic Quality of Life
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
21 Years to 85 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Phoenix, Arizona • Anaheim, California • Fresno, California + 27 more
Conditions
Obesity and Type 2 Diabetes
Interventions
NT-0796, Placebo
Drug
Lead sponsor
Rezera (formerly NodThera Limited)
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
11
States / cities
Mesa, Arizona • Los Angeles, California • Cooper City, Florida + 8 more
Conditions
Obesity, Overweight
Interventions
Maridebart cafraglutide, Autoinjector
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
The Villages, Florida
Conditions
Diabetic Foot Ulcer, Diabetic Neuropathy, Type 2 Diabetes
Interventions
Diabetic Foot Ulcer Biopsy, Survey, Comprehensive Neuropathy Assessment, Wound Photography
Procedure · Other
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Mineola, New York
Conditions
Obesity, Overweight, Type 2 Diabetes
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Sun City West, Arizona • Tucson, Arizona • San Ramon, California + 31 more
Completed Phase 2 Interventional Results available

A Study of LY2189102 in Patients With Type 2 Diabetes

NCT00942188
Conditions
Type 2 Diabetes
Interventions
LY2189102, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Mobile, Alabama • Anaheim, California • Chula Vista, California + 15 more